About: Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
Creator	Fouchier, Ron Rimmelzwaan, Guus Sutter, Gerd Volz, Asisa Altenburg, Arwen De Swart, Rik Macloughlin, Ronan Van Amerongen, Geert De Vries, Rory Hendriks, Rudi Li, Bobby Van De Sandt, Carolien
topic	covid:9eb3ea6224aabe868a10af37dc829b9636be5856#this
Source	PMC
abstract	Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vitro, ex vivo and in vivo experiments with recombinant MVA expressing green fluorescent protein (rMVA-GFP). In both human peripheral blood mononuclear cells and mouse lung explants, rMVA-GFP predominantly infected antigen presenting cells. Subsequent in vivo experiments performed in mice, ferrets and non-human primates indicated that preferential targeting of dendritic cells and alveolar macrophages was observed after respiratory administration, although subtle differences were observed between the respective animal species. Following intramuscular injection, rMVA-GFP was detected in interdigitating cells between myocytes, but also in myocytes themselves. These data are important in advancing our understanding of the basis for the immunogenicity of MVA-based vaccines and aid rational vaccine design and delivery strategies.
has issue date	2017-08-17(xsd:dateTime)
bibo:doi	10.1038/s41598-017-08719-y
bibo:pmid	28819261
has license	cc-by
sha1sum (hex)	9eb3ea6224aabe868a10af37dc829b9636be5856
schema:url	https://doi.org/10.1038/s41598-017-08719-y
resource representing a document's title	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
has PubMed Central identifier	PMC5561217
has PubMed identifier	28819261
schema:publication	Sci Rep
resource representing a document's body	covid:9eb3ea6224aabe868a10af37dc829b9636be5856#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/9eb3ea6224aabe868a10af37dc829b9636be5856
is schema:about of	named entity 'OUR' named entity 'MYOCYTES' named entity 'DELIVERY' named entity 'INTRAMUSCULAR INJECTION' named entity 'INTERDIGITATING CELLS' named entity 'VACCINES' named entity 'BUT' named entity 'IMPORTANT' named entity 'STRATEGIES' named entity 'respective' covid:arg/9eb3ea6224aabe868a10af37dc829b9636be5856 named entity 'ADMINISTRATION' named entity 'AID' named entity 'DATA' named entity 'BASED' named entity 'MVA' named entity 'BASIS' named entity 'THESE' named entity 'GFP' named entity 'ADVANCING' named entity 'OBSERVED' named entity 'FOLLOWING' named entity 'IMMUNOGENICITY' named entity 'RESPIRATORY' named entity 'DETECTED' named entity 'ANIMAL SPECIES' named entity 'UNDERSTANDING' named entity 'aid' named entity 'intramuscular injection' named entity 'myocytes' named entity 'intramuscular injection' named entity 'Mustela' named entity 'GFP' named entity 'medetomidine' named entity 'Blood samples' named entity 'APC' named entity 'Roche diagnostics' named entity 'non-human primates' named entity 'HLA' named entity 'phenotypically' named entity 'IM injection' named entity 'alveolar macrophages' named entity 'CLSM' named entity 'FACS' named entity 'biotin' named entity 'AER' named entity 'amphotericin' named entity 'Lonza' named entity 'NALT' named entity 'CD11c' named entity 'lysis buffer' named entity 'CD19' named entity 'inhalation' named entity 'GFP' named entity 'phenotype' named entity 'GFP' named entity 'infection' named entity 'inoculation' named entity 'present antigens' named entity 'non-human primates' named entity 'GFP' named entity 'PCR' named entity 'Vaccination' named entity 'inoculation' named entity 'neutrophils' named entity 'HPA' named entity 'CD11c' named entity 'refractory'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software